Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings Inc (NYSE American: SENS) is a pioneer in long-term implantable continuous glucose monitoring systems, transforming diabetes care through innovative medical technology. This news hub provides investors and healthcare professionals with timely updates on corporate developments, regulatory milestones, and clinical advancements.
Access official press releases covering financial results, product approvals, and strategic partnerships alongside analysis of key operational updates. Our curated news collection includes updates on Eversense CGM system enhancements, international market expansions, and clinical study outcomes.
Stay informed about critical developments including FDA submissions, European regulatory updates, and partnership announcements with global healthcare distributors. Bookmark this page for direct access to primary source materials essential for tracking Senseonics' progress in medical device innovation.
Senseonics Holdings, Inc. (NYSE American: SENS) announced its participation in the Morgan Stanley Global Healthcare Conference on September 13, 2022, at 7:20 am ET in New York, NY. The event will include one-on-one meetings, and interested parties can access a live and recorded webcast via the company's website at www.senseonics.com. Senseonics specializes in long-term, implantable continuous glucose monitoring systems, aiming to enhance the lives of those with diabetes.
Senseonics Holdings, Inc. (AMEX: SENS) announced the transition of its Chief Financial Officer, Nick Tressler, effective September 1, 2022. Rick Sullivan, the current Vice President of Finance, will succeed Tressler. The company emphasizes Sullivan's proven track record and leadership abilities to enhance operational and financial performance. Tressler will remain with Senseonics in a supporting role until the end of the year. The transition is expected to continue the company's strategic initiatives in the medical technology sector, specifically in long-term glucose monitoring systems.
Senseonics Holdings, Inc. (NYSE American: SENS) plans to present at the Inaugural Gilmartin Group Emerging Showcase virtually on August 31, 2022, at 3:00pm ET. The company specializes in developing long-term, implantable continuous glucose monitoring systems for diabetes management. Interested parties can access a live and archived webcast of the presentation on the company’s website at www.senseonics.com. The Eversense® CGM systems provide real-time glucose data through a small sensor under the skin, enhancing diabetes care.
Senseonics Holdings, Inc. (NYSE American: SENS) reported a revenue of $3.7 million for Q2 2022, up from $3.3 million in Q2 2021. The U.S. revenue increased to $1.2 million from $1.0 million year-over-year. Gross profit improved to $0.8 million, up from $0.4 million. Notably, the company recorded a net income of $104.2 million, attributed to adjustments in embedded derivatives. Senseonics also reaffirmed its full-year revenue guidance of $14.0 million to $18.0 million. Recent highlights included CE mark approval for the E3 system and improved patient access through coverage decisions.
Senseonics Holdings, Inc. (AMEX: SENS) announced that Anthem is providing coverage for its Eversense E3 Continuous Glucose Monitoring (CGM) System, adding over 45 million covered lives. This expands the total coverage for Eversense to approximately 250 million lives in the U.S. The Eversense CGM offers a six-month sensor life, accurate glucose data, and remote monitoring capabilities for diabetes management. The decision follows similar coverage expansions by other major insurers, enhancing the accessibility of this advanced monitoring technology.
Senseonics Holdings, Inc. (NYSE American: SENS) announced plans to release its Q2 2022 financial results on August 9, 2022, after market close. Management will review the performance during a conference call at 4:30 p.m. (ET), which will be available via a webcast on the company's website. Senseonics specializes in long-term implantable continuous glucose monitoring (CGM)
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants to 17 new non-executive employees under its 2019 Inducement Plan. Each employee received non-qualified stock options to purchase 199,000 shares at an exercise price of $1.02 per share, corresponding to the closing price on July 1, 2022. The options will vest over four years, contingent on continued employment. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management globally.
Senseonics Holdings, Inc. has received CE Mark approval for the Eversense® E3 CGM System, allowing commercialization in select European markets. The E3 system is the longest-lasting continuous glucose monitoring device, with a wear duration of up to 6 months and superior accuracy. Ascensia Diabetes Care, Senseonics’ commercial partner, will launch the product in Germany, Italy, Spain, and other EU countries starting Q3 2022. The E3 system enhances operational efficiency and supports non-adjunctive use, improving treatment decisions without confirmatory fingerstick tests.
Senseonics Holdings, Inc. (AMEX: SENS) announced its participation in the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022, at 1:30pm ET. The presentation will be accessible via a live and recorded webcast on the company's website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, including Eversense® devices, designed to aid diabetes management. The company aims to transform lives by providing innovative glucose monitoring solutions.
Senseonics Holdings, Inc. (AMEX: SENS) has announced its participation in the hybrid H.C. Wainwright Global Investment Conference on May 24, 2022. Management will engage in virtual one-on-one meetings, with a webcast presentation starting at 7:00 AM ET. The company specializes in implantable continuous glucose monitoring (CGM) systems, aimed at enhancing diabetes management. Their products include Eversense®, Eversense® XL, and Eversense® E3, which transmit glucose data to smartphones every five minutes.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
